{"id":20545,"date":"2021-05-05T06:55:22","date_gmt":"2021-05-05T05:55:22","guid":{"rendered":"https:\/\/www.curiumpharma.com\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/"},"modified":"2021-05-05T06:55:22","modified_gmt":"2021-05-05T05:55:22","slug":"radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines","status":"publish","type":"post","link":"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/","title":{"rendered":"RadioMedix &#038; Curium Announce Detectnet\u2122 (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines\u00ae"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":65,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[94],"tags":[],"class_list":["post-20545","post","type-post","status-publish","format-standard","hentry","category-comunicados-de-prensa"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RadioMedix &amp; Curium Announce Detectnet\u2122 (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines\u00ae - Curium Pharma<\/title>\n<meta name=\"description\" content=\"RadioMedix Inc. and Curium announced that Detectnet is now included in the NCCN Clinical Practice Guidelines in Oncology \u2013 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RadioMedix &amp; Curium Announce Detectnet\u2122 (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines\u00ae - Curium Pharma\" \/>\n<meta property=\"og:description\" content=\"RadioMedix Inc. and Curium announced that Detectnet is now included in the NCCN Clinical Practice Guidelines in Oncology \u2013 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/\" \/>\n<meta property=\"og:site_name\" content=\"Curium Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-05T05:55:22+00:00\" \/>\n<meta name=\"author\" content=\"Lauren Haynes\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lauren Haynes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2021\\\/05\\\/05\\\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2021\\\/05\\\/05\\\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\\\/\"},\"author\":{\"name\":\"Lauren Haynes\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/9dfd1bf1b3e0c90cb6cc5575b80603ba\"},\"headline\":\"RadioMedix &#038; Curium Announce Detectnet\u2122 (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines\u00ae\",\"datePublished\":\"2021-05-05T05:55:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2021\\\/05\\\/05\\\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\\\/\"},\"wordCount\":12,\"articleSection\":[\"Comunicados de prensa\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2021\\\/05\\\/05\\\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\\\/\",\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2021\\\/05\\\/05\\\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\\\/\",\"name\":\"RadioMedix & Curium Announce Detectnet\u2122 (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines\u00ae - Curium Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#website\"},\"datePublished\":\"2021-05-05T05:55:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/9dfd1bf1b3e0c90cb6cc5575b80603ba\"},\"description\":\"RadioMedix Inc. and Curium announced that Detectnet is now included in the NCCN Clinical Practice Guidelines in Oncology \u2013 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2021\\\/05\\\/05\\\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2021\\\/05\\\/05\\\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/2021\\\/05\\\/05\\\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RadioMedix &#038; Curium Announce Detectnet\u2122 (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/\",\"name\":\"Curium Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curiumpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/9dfd1bf1b3e0c90cb6cc5575b80603ba\",\"name\":\"Lauren Haynes\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g\",\"caption\":\"Lauren Haynes\"},\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/es\\\/author\\\/lauren-haynes03gmail-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RadioMedix & Curium Announce Detectnet\u2122 (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines\u00ae - Curium Pharma","description":"RadioMedix Inc. and Curium announced that Detectnet is now included in the NCCN Clinical Practice Guidelines in Oncology \u2013 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/","og_locale":"es_ES","og_type":"article","og_title":"RadioMedix & Curium Announce Detectnet\u2122 (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines\u00ae - Curium Pharma","og_description":"RadioMedix Inc. and Curium announced that Detectnet is now included in the NCCN Clinical Practice Guidelines in Oncology \u2013 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).","og_url":"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/","og_site_name":"Curium Pharma","article_published_time":"2021-05-05T05:55:22+00:00","author":"Lauren Haynes","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Lauren Haynes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/#article","isPartOf":{"@id":"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/"},"author":{"name":"Lauren Haynes","@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/9dfd1bf1b3e0c90cb6cc5575b80603ba"},"headline":"RadioMedix &#038; Curium Announce Detectnet\u2122 (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines\u00ae","datePublished":"2021-05-05T05:55:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/"},"wordCount":12,"articleSection":["Comunicados de prensa"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/","url":"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/","name":"RadioMedix & Curium Announce Detectnet\u2122 (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines\u00ae - Curium Pharma","isPartOf":{"@id":"https:\/\/www.curiumpharma.com\/#website"},"datePublished":"2021-05-05T05:55:22+00:00","author":{"@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/9dfd1bf1b3e0c90cb6cc5575b80603ba"},"description":"RadioMedix Inc. and Curium announced that Detectnet is now included in the NCCN Clinical Practice Guidelines in Oncology \u2013 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).","breadcrumb":{"@id":"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.curiumpharma.com\/es\/2021\/05\/05\/radiomedix-curium-announce-detectnet-copper-cu-64-dotatate-injection-inclusion-on-nccn-guidelines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curiumpharma.com\/es\/"},{"@type":"ListItem","position":2,"name":"RadioMedix &#038; Curium Announce Detectnet\u2122 (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.curiumpharma.com\/#website","url":"https:\/\/www.curiumpharma.com\/","name":"Curium Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curiumpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/9dfd1bf1b3e0c90cb6cc5575b80603ba","name":"Lauren Haynes","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/67a67a73bfdc11a26a099f3658725fa76f7e28daa31f6367899649c714fdda91?s=96&d=mm&r=g","caption":"Lauren Haynes"},"url":"https:\/\/www.curiumpharma.com\/es\/author\/lauren-haynes03gmail-com\/"}]}},"_links":{"self":[{"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/posts\/20545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/users\/65"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/comments?post=20545"}],"version-history":[{"count":0,"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/posts\/20545\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/media?parent=20545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/categories?post=20545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curiumpharma.com\/es\/wp-json\/wp\/v2\/tags?post=20545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}